News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Kiadis Pharma Announces Continued Collaboration With Professor Velardi on its Lead Product ATIR(TM)


12/1/2008 9:53:17 AM

AMSTERDAM, November 28 /PRNewswire/ -- Oncology focused biopharmaceutical company Kiadis Pharma announces today that Andrea Velardi, M.D., Professor of Clinical Immunology at the University of Perugia, Italy and Kiadis Pharma are continuing their collaboration on ATIR(TM), a product in clinical development for enabling the use of a mismatched donor in a bone marrow transplantation by preventing acute Graft versus Host Disease (GvHD) for end stage leukemia patients. Under the agreement Professor Velardi will continue the development on the selective depletion of allo-reactive T cells from mismatched donors using Kiadis Pharma's ATIR(TM). Kiadis Pharma is preparing for a multi-center pivotal study on ATIR(TM) to start early 2009 and Professor Velardi will participate in this upcoming study.

"We are very pleased with our continued collaboration with the University of Perugia and Professor Velardi, who is a leader in the field of mismatched bone marrow transplantations," says Dr. Manja Bouman, CEO of Kiadis Pharma. "This collaboration is an important milestone in the development of ATIR(TM) as a revolutionary approach to provide safe and potentially life-saving mismatched bone marrow transplantations as a treatment option for end-stage leukemia patients."

Professor Andrea Velardi says: "So far, we have treated 25 blood cancer patients who have received bone marrow from mismatched donors, including donor immune cells that are selectively depleted of cells causing acute Graft versus Host Disease using the ATIR(TM) process. The results so far are promising and I am therefore very pleased to continue to work with Kiadis Pharma in this field."

For the complete press release please go to: http://www.kiadis.com/news

About Kiadis Pharma

Kiadis Pharma is an oncology focused pharmaceutical development company with three products in different phases of clinical development. The company develops products that offer novel treatment options for terminally ill cancer patients and address significant unmet medical needs. The key focus indication for Kiadis Pharma is limitations and complications of bone marrow transplantation procedures performed in blood cancer patients. Kiadis Pharma is headquartered in Amsterdam, The Netherlands with facilities in Groningen, The Netherlands and Montreal, Canada. For more information about Kiadis Pharma, please visit http://www.kiadis.com.

English release is provided by Kiadis Pharma. Equivalent translations are from a third party.

CONTACT: For more information: Kiadis Pharma B.V., Eefje Simpelaar,
Director Communications, Email: e.simpelaar@kiadis.com, Tel:
+31-20-3140250, Mob: +31-61-0829344


Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES